Anthropometry in Children with Transfusion-Dependent Beta-Thalassemia Major
DOI:
https://doi.org/10.51253/pafmj.v73i6.5814Keywords:
Anthropometry, β-Thalassemia major, Socio-demographic variablesAbstract
Objective: To determine the abnormal anthropometric findings among children diagnosed with and managed for transfusiondependent beta-thalassemia major.
Study Design: Cross-sectional study.
Place and Duration of Study: Department of Paediatric Medicine, Pak Emirates Military Hospital, Rawalpindi Pakistan, from
Sep 2019 to Aug 2020.
Methodology: This study involved 310 children of both genders aged 2 to 18 years presenting with beta-thalassemia Major receiving multiple blood transfusions. Anthropometric findings, including height and weight for age, were measured and plotted via World Health Organization-2007 growth charts in all the study participants. Relevant socio-demographic variables, including serum ferritin, were correlated with abnormal anthropometric findings among these children.
Results: The mean age of the patients was 8.87±7.42 years. 170(54.8%) male and 140(45.2%) female patients were in the study group. Most of the children [218 (70.3%)] had any abnormal an-thropometric findings, either weight or height for age, while 92 (29.7%) had no anthropometric abnormality. Majority of the patients [198 (63.8%)] patients had stunted growth, while 170 (54.8%) were underweight. Longer duration of transfusion and raised serum ferritin levels had a statistically significant correlation with any anthropometric abnormality among the beta-thalassemia major patients (p-value<0.05).
Conclusion: More than 70% of the patients suffering from beta thalassemia major had abnormal anthropometric findings.
Height was affected more than weight among these individuals. Patients with longer duration of transfusion dependence and raised serum ferritin levels were more at risk of developing anthropometric abnormality in our target population.
Downloads
Metrics
References
Bajwa H, Basit H. Thalassemia. In: StatPearls. Treasure Island(FL): StatPearls Publishing; 2020, Avaliblity:https://www.ncbi.nlm.nih.gov/books/NBK545151/
Qurat-ul-Ain, Ahmad L, Hassan M, Rana SM, Jabeen F. Prevalence of β-thalassemic patients associated with consanguinity
and anti-HCV-antibody positivity–a cross sectional study. Pak JZool 2011; 43(1): 29-36.
Ansari SH, Shamsi TS, Ashraf M, Bohray M, Farzana T, KhanMT, et al. Molecular epidemiology of β-thalassemia in Pakistan:
far reaching implications. Int J Mol Epidemiol Genet 2011; 2(4):403-408.
Vichinsky E, Neumayr L, Trimble S, Giardina PJ, Cohen AR,Coates T, et al. Transfusion complications in thalassemia
patients: a report from the Centers for Disease Control andPrevention (CME). Transfusion 2014; 54(4): 972-981.https://doi.org/10.1111/trf.12348
Teawtrakul N, Jetsrisuparb A, Pongudom S. Epidemiologicstudy of major complications in adolescent and adult patients
with thalassemia in Northeastern Thailand: the E-SAAN studyphase I. Hematology 2018; 23(1): 55-606. https://doi.org/10.1080/10245332.2017.1358845
Bayanzay K, Alzoebie L. Reducing the iron burden andimproving survival in transfusion-dependent thalassemia
patients: current. J Blood Med 2016; 7(1): 159-169.https://doi.org/10.2147/JBM.S61540.
Moayeri H, Oloomi Z. Prevalence of growth and puberty failurewith respect to growth hormone and gonadotropins secretion inbeta-thalassemia major. Arch Iran Med 2006; 9(4): 329-334.
De Sanctis V, Soliman AT, Elsedfy H, Skordis N, Kattamis C,Angastiniotis M, et al. Growth and endocrine disorders inthalassemia: The international network on endocrinecomplications in thalassemia (I-CET) position statement andguidelines. Indian J Endocr Metab 2013; 17(1): 8-18.https://doi.org/10.4103%2F2230-8210.107808
Rathaur VK, Imran A, Pathania M. Growth pattern inthalassemic children and their correlation with serum ferritin. J
Family Med Prim Care 2020; 9(2): 1166-1169.https://doi.org/10.4103/jfmpc.jfmpc_951_19
Moiz B, Habib A, Sawani S, Raheem A, Hasan B, Gangwani M.Anthropometric measurements in children having transfusiondependent beta thalassemia. Hematology 2018; 23(4): 248-252.https://doi.org/10.1080/10245332.2017.
Yassin MA, Soliman AT, De Sanctis V, Yassin KS, Abdulla MA.Final Height and Endocrine Complications in Patients with βThalassemia Intermedia: Our Experience in Non-TransfusedVersus Infrequently Transfused Patients and Correlations with
Liver Iron Content. Mediterr J Hematol Infect Dis 2019; 11(1):e2019026. https://doi.org/10.4084/MJHID.2019.026
Lee YK, Kim HJ, Lee K, Park SH, Song SH, Seong MW, et al.Recent progress in laboratory diagnosis of thalassemia and
hemoglobinopathy: a study by the Korean Red Blood CellDisorder Working Party of the Korean Society of Hematology.
Blood Res 2019; 54(1): 17-22.https://doi.org/10.5045/br.2019.54.1.17
Preedy V. Handbook of anthropometry. 1st Edition, New York(NY): Springer; 2012, Avalibilty:https://ftp.idu.ac.id/wp-content/uploads
McDowell LA, Kudaravalli P, Sticco KL. Iron Overload. In:StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
Sharma R, Seth A, Chandra J, Gohain S. Endocrinopathies inadolescents with thalassaemia major receiving oral iron
chelation therapy. Paediatr Int Child Health 2016; 36(1): 22-27.https://doi.org/10.1179/2046905514Y.0000000160
Dhouib NG, Ben Khaled M, Ouederni M, Besbes H, Kouki R,Mellouli F, et al. Growth and Endocrine Function in Tunisian
Thalassemia Major Patients. Mediterr J Hematol Infect Dis 2018;10(1): e2018031. https://doi.org/10.4084/MJHID.2018.031
Toumba M, Sergis A, Kanaris C, Skordis N. Endocrinecomplications in patients with Thalassaemia Major. Pediatr
Endocrinol Rev 2007; 5(2): 642-648.
Delvecchio M, Cavallo L. Growth and endocrine function inthalassemia major in childhood and adolescence. J Endocrinol
Invest 2010; 33(1): 61-68. https://doi.org/10.1007/BF03346551
Downloads
Published
How to Cite
Issue
Section
